Immunity Booster Blend Injectable 10mg/ml 10vials 1 kits

Description

Immunity Booster Thymic Peptide Injectable Research

Specification Sheet

• Active Agents: Thymosin Alpha-1, Thymalin
• CAS Number: 62304-98-7 (Thymosin Alpha-1) / 63958-90-7 (Thymalin)
• Molecular Formula: C109H159N25O36 (Thymosin Alpha-1)
• Molecular Weight: 3108.3 g/mol (Thymosin Alpha-1)
• Purity: >99.0% via HPLC-UV
• Appearance: Sterile white lyophilized powder cake

Pharmacodynamics

The biochemical activity of this dual-peptide blend is defined by its concurrent engagement of the thymus gland and peripheral cellular immunity networks. Initially, Thymosin Alpha-1 interacts with toll-like receptors (TLRs) to augment the activity of dendritic cells. This defines the first semantic triple: [Thymosin Alpha-1 stimulates T-cell maturation]. Secondly, Thymalin penetrates the nucleus of target lymphocytes to promote gene transcription of pro-inflammatory and anti-inflammatory mediators. This establishes the second triple: [Thymalin upregulates cytokine production]. Furthermore, this synchronized thymic signaling cascade increases the presentation of antigens on the cellular surface. This forms the third triple: [Thymic peptides enhance MHC class-I expression]. Quantitatively, while Thymosin Alpha-1 possesses a systemic half-life of approximately 2 hours ($t_{1/2}=2.0pm0.4$h) in mammalian models, the resulting cascade of natural killer (NK) cell proliferation sustains immune activation for several days. In comparative studies, this thymic blend is distinguished from the tripeptide KPV; while standalone KPV strictly exerts localized anti-inflammatory effects via NF-kB inhibition, the Thymosin Alpha-1 and Thymalin blend actively drives systemic immune up-regulation and coordinates broad-spectrum cellular defense responses.

Overview

The Immunity Booster blend is a synergistic, multi-target peptide formulation combining the biologically active thymic hormones Thymosin Alpha-1 and Thymalin. [The blend modulates cellular immunity]. This formulation serves as a primary research benchmark for investigating the neuroendocrine regulation of immune senescence and the acceleration of macrophage phagocytosis. Its dual-pathway architecture allows for high-fidelity studies on the restoration of youthful immune surveillance and T-cell lineage maturation.

Experimental Outcomes

• Enhanced Cellular Surveillance: Users in research models report profound increases in resilience against seasonal pathogens via elevated natural killer cell activity.
• Accelerated Recovery: Published research indicates rapid recovery from systemic fatigue and post-exertional immunosuppression.
• Inflammatory Modulation: Based on community feedback, research models show a marked balancing of Th1 and Th2 cytokine profiles.
• Connective Tissue Support: Cumulative findings indicate optimized tissue repair kinetics during active localized inflammation.
• Senescence Mitigation: Research models have observed a delay in T-cell exhaustion markers during prolonged physiological stress.

In Brief:
The Immunity Booster blend represents a premier, non-hormonal research tool for investigating the synergistic amplification of cellular immunity and thymic regulation.

Frequently Asked Questions

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before use.